Extensions to the Visual Predictive Check to facilitate model performance evaluation

被引:182
作者
Post, Teun M. [2 ]
Freijer, Jan I. [4 ]
Ploeger, Bart A. [1 ,3 ]
Danhof, Meindert [1 ,3 ]
机构
[1] Leiden Univ, Leiden Amsterdam Ctr Drug Res, Div Pharmacol, NL-2300 RA Leiden, Netherlands
[2] NV Organon, NL-5340 BH Oss, Netherlands
[3] Leiden Experts Adv Pharmacokinet & Pharmacodynam, Leiden, Netherlands
[4] Astellas Pharma, Leiderdorp, Netherlands
关键词
Visual Predictive Check; pharmacokinetics; pharmacodynamics; disease progression; evaluation; validation; qualification; model performance;
D O I
10.1007/s10928-007-9081-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The Visual Predictive Check (VPC) is a valuable and supportive instrument for evaluating model performance. However in its most commonly applied form, the method largely depends on a subjective comparison of the distribution of the simulated data with the observed data, without explicitly quantifying and relating the information in both. In recent adaptations to the VPC this drawback is taken into consideration by presenting the observed and predicted data as percentiles. In addition, in some of these adaptations the uncertainty in the predictions is represented visually. However, it is not assessed whether the expected random distribution of the observations around the predicted median trend is realised in relation to the number of observations. Moreover the influence of and the information residing in missing data at each time point is not taken into consideration. Therefore, in this investigation the VPC is extended with two methods to support a less subjective and thereby more adequate evaluation of model performance: (i) the Quantified Visual Predictive Check (QVPC) and (ii) the Bootstrap Visual Predictive Check (BVPC). The QVPC presents the distribution of the observations as a percentage, thus regardless the density of the data, above and below the predicted median at each time point, while also visualising the percentage of unavailable data. The BVPC weighs the predicted median against the 5th, 50th and 95th percentiles resulting from a bootstrap of the observed data median at each time point, while accounting for the number and the theoretical position of unavailable data. The proposed extensions to the VPC are illustrated by a pharmacokinetic simulation example and applied to a pharmacodynamic disease progression example.
引用
收藏
页码:185 / 202
页数:18
相关论文
共 23 条
[1]   Impact of pharmacometric reviews on new drug approval and labeling decisions - a survey of 31 new drug applications submitted between 2005 and 2006 [J].
Bhattaram, V. A. ;
Bonapace, C. ;
Chilukuri, D. M. ;
Duan, J. Z. ;
Garnett, C. ;
Gobburu, J. V. S. ;
Jang, S. H. ;
Kenna, L. ;
Lesko, L. J. ;
Madabushi, R. ;
Men, Y. ;
Powell, J. R. ;
Qiu, W. ;
Ramchandani, R. P. ;
Tornoe, C. W. ;
Wang, Y. ;
Zheng, J. J. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (02) :213-221
[2]   Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated?: A survey of the literature from 2002 to 2004 [J].
Brendel, Karl ;
Dartois, Celine ;
Comets, Emmanuelle ;
Lemenuel-Diot, Annabelle ;
Laveille, Christian ;
Tranchand, Brigitte ;
Girard, Pascal ;
Laffont, Celine M. ;
Mentre, France .
CLINICAL PHARMACOKINETICS, 2007, 46 (03) :221-234
[3]   Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide [J].
Brendel, Karl ;
Comets, Emmanuelle ;
Laffont, Celine ;
Laveille, Christian ;
Mentre, France .
PHARMACEUTICAL RESEARCH, 2006, 23 (09) :2036-2049
[4]   Drug treatment effects on disease progression [J].
Chan, PLS ;
Holford, NHG .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2001, 41 :625-659
[5]   A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying type 2 diabetes mellitus [J].
de Winter, Willem ;
DeJongh, Joost ;
Post, Teun ;
Ploeger, Bart ;
Urquhart, Richard ;
Moules, Ian ;
Eckland, David ;
Danhof, Meindert .
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2006, 33 (03) :313-343
[6]   Population pharmacokinetics of humanized monoclonal antibody HuCC49ΔCH2 and murine antibody CC49 in colorectal cancer patients [J].
Fang, Lanyan ;
Holford, Nicholas H. G. ;
Hinkle, George ;
Cao, Xianhua ;
Xiao, Jim J. ;
Bloomston, Mark ;
Gibbs, Seth ;
Al Saif, Osama Habib ;
T Dalton, James ;
Chan, Kenneth K. ;
Schlom, Jeffery ;
Martin, Edward W., Jr. ;
Sun, Duxin .
JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (02) :227-237
[7]   Multiple imputation for model checking: Completed-data plots with missing and latent data [J].
Gelman, A ;
Van Mechelen, I ;
Verbeke, G ;
Heitjan, DF ;
Meulders, M .
BIOMETRICS, 2005, 61 (01) :74-85
[8]   Analysis of toxicokinetic data using NONMEM: Impact of quantification limit and replacement strategies for censored data [J].
Hing, JP ;
Woolfrey, SG ;
Greenslade, D ;
Wright, PMC .
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2001, 28 (05) :465-479
[9]  
HOLFORD N, 2006, PKPD MODEL CATHEPSIN
[10]  
Holford N, 2005, VISUAL PREDICTIVE CH, P14